Cargando…

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin

Protamine, the only registered antidote of unfractionated heparin (UFH), may produce a number of adverse effects, such as anaphylactic shock or serious hypotension. We aimed to develop an alternative UFH antidote as efficient as protamine, but safer and easier to produce. As a starting material, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalaska, Bartlomiej, Kaminski, Kamil, Sokolowska, Emilia, Czaplicki, Dominik, Kujdowicz, Monika, Stalinska, Krystyna, Bereta, Joanna, Szczubialka, Krzysztof, Pawlak, Dariusz, Nowakowska, Maria, Mogielnicki, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362941/ https://www.ncbi.nlm.nih.gov/pubmed/25781030 http://dx.doi.org/10.1371/journal.pone.0119486

Ejemplares similares

The Toxicokinetic Profile of Dex40-GTMAC3—a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin
por: Sokolowska, Emilia, et al.
Publicado: (2016)

The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents
por: Miklosz, Joanna, et al.
Publicado: (2019)

The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target
por: Kalaska, Bartlomiej, et al.
Publicado: (2019)

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins
por: Jakimczuk, Aleksandra, et al.
Publicado: (2022)

Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice
por: Swieton, Justyna, et al.
Publicado: (2021)

Inactivation of Heparin by Cationically Modified Chitosan
por: Lorkowska-Zawicka, Barbara, et al.
Publicado: (2014)

The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review
por: Frackiewicz, Aleksandra, et al.
Publicado: (2023)

Monitoring of Cardiorespiratory Parameters in Rats—Validation Based on Pharmacological Stimulation
por: Miklosz, Joanna, et al.
Publicado: (2021)

The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats
por: Kalaska, Bartlomiej, et al.
Publicado: (2022)

Biological Properties of Heparins Modified with an Arylazopyrazole-Based Photoswitch
por: Stolarek, Marta, et al.
Publicado: (2023)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models
por: Miklosz, Joanna, et al.
Publicado: (2021)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments
por: Davenport, Andrew
Publicado: (2012)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin
por: Workman, Wesley E., et al.
Publicado: (2020)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Resistance to unfractionated heparin in the ICU: evaluation and management options
por: Levy, Jerrold H., et al.
Publicado: (2023)

shRNAs targeting mouse Adam10 diminish cell response to proinflammatory stimuli independently of Adam10 silencing
por: Czarnek, Maria, et al.
Publicado: (2022)

Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome
por: Seaman, Craig D., et al.
Publicado: (2020)

Kynurenine Pathway in Chronic Kidney Disease: What’s Old, What’s New, and What’s Next?
por: Mor, Adrian, et al.
Publicado: (2020)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory
por: Kim, Moo Hyun, et al.
Publicado: (2014)

Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer
por: Hermanowicz, Justyna Magdalena, et al.
Publicado: (2021)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin
por: Maharaj, Satish, et al.
Publicado: (2018)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Mouse Antibody of IgM Class is Prone to Non-Enzymatic Cleavage between CH1 and CH2 Domains
por: Klaus, Tomasz, et al.
Publicado: (2018)

Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401
por: Mor, Adrian, et al.
Publicado: (2020)

Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
por: Kapur, Navin K., et al.
Publicado: (2012)

Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity
por: Li, Binghan, et al.
Publicado: (2016)

Individual variation in unfractionated heparin dosing after pediatric cardiac surgery
por: Hikino, Keiko, et al.
Publicado: (2020)

Validation of high concentrated thrombin time assay for unfractionated heparin monitoring
por: Apipongrat, Dollapak, et al.
Publicado: (2022)

Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach
por: Abdel-Hafez, Ahmad, et al.
Publicado: (2022)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Dynamic Combinatorial Optimization of In Vitro and In Vivo Heparin Antidotes
por: Carbajo, Daniel, et al.
Publicado: (2022)

A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris
por: Amane, Hanmant S., et al.
Publicado: (2011)

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
por: Nicholson, Tricia, et al.
Publicado: (2001)

Impact of nebulized unfractionated heparin and N-acetylcysteine in management of smoke inhalation injury
por: Elamin, E, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_navc1tjuipn1hquq4er9stitjm